rp1
Biologicalexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Sep 20, 2017 (NCT03767348)
Timeline
Indications
Studied for
- Basal Cell Carcinoma · Phase 1
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 2
- DNA Mismatch Repair · Phase 1/Phase 2
- Drug Therapy · Phase 1/Phase 2
- Hemangiosarcoma · Phase 2
- Melanoma · Phase 3
- Microsatellite Instability · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650271 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06898970 | Phase 2 | Oct 31, 2025 | Replimune Inc., University of California, San Francisco |
| NCT06264180 | Phase 3 | Jul 11, 2024 | Replimune Inc. |
| NCT06216938 | Early Phase 1 (Phase 1) | Feb 2, 2024 | Replimune Inc., University of Pittsburgh |
| NCT05858229 | Phase 1/Phase 2 (Phase 2) | Jun 16, 2023 | Rochester Dermatologic Surgery |
| NCT04349436 | Phase 1 | Apr 30, 2020 | Replimune Inc. |
| NCT04050436 | Phase 2 | Aug 31, 2019 | Regeneron, Replimune Inc., University of California, San Francisco |
| NCT03767348 | Phase 1/Phase 2 (Phase 2) | Sep 20, 2017 | Replimune Inc. |
| NCT06590480 | N/A | — | Replimune Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Replimune Inc. | For profit | 7 | 5 | 4 | 2017 |
| University of California, San Francisco | Academic/Hospital | 2 | 1 | 1 | 2019 |
| Regeneron | For profit | 1 | 0 | 1 | 2019 |
| Rochester Dermatologic Surgery | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1